Philips CPAP recall lawsuit: where MDL 3014 actually stands after the $1.1 billion settlement

The Philips CPAP litigation has produced one of the most consequential mass tort resolutions of the past several years. MDL 3014 (In re: Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation), centralized in the U.S. District Court for the Western District of Pennsylvania before Senior Judge Joy Flowers Conti, consolidates the federal personal injury and economic loss claims arising from Philips's June 2021 recall of approximately 3.5 million sleep apnea and ventilator devices. The recall stemmed from Philips's belated acknowledgment that the polyester-based polyurethane (PE-PUR) sound abatement foam used in the devices could degrade over time, releasing particles and chemicals that users inhaled.

The litigation was largely resolved through two major settlements. In September 2023, Philips agreed to a $445 million class-action settlement to resolve economic loss claims (consumers seeking compensation for the cost of recalled devices). In April 2024, Philips announced a $1.075 billion settlement to resolve personal injury claims arising from device use, plus $25 million for medical monitoring claims, for a combined $1.1 billion personal injury settlement framework. The settlements covered most personal injury claims in MDL 3014 and parallel state court actions, though some cases remain outside the settlement framework.

As of mid-2026, the procedural posture is complex. Most personal injury cases have been resolved through the settlement. Some cases remain in state court tracks where Philips couldn't successfully remove them to federal MDL (January 2026 Kentucky remand being a notable example). The Department of Justice and FDA enforcement actions related to the recall continue separately. The consent decree between Philips Respironics and the FDA places ongoing manufacturing restrictions on the company. Internal documents revealed during litigation discovery showing that Philips received foam-related complaints as early as 2008 (more than a decade before the public recall) have produced ongoing reputational and regulatory consequences beyond the civil settlements.

This is the device defect that produced the recall, the procedural history of MDL 3014, the structure of the $1.1 billion settlement framework, who qualifies for participation, and what's still being litigated for cases outside the federal settlement.

The device defect

Philips Respironics manufactured CPAP (Continuous Positive Airway Pressure), BiPAP (Bilevel Positive Airway Pressure), and mechanical ventilator devices used by millions of people for sleep apnea, COPD, and other respiratory conditions. The devices use compressed air delivered through a mask or tube to support breathing.

The defective component was the sound abatement foam used to reduce device noise. The foam was made from polyester-based polyurethane (PE-PUR), which Philips claimed at the time was an industry-standard material for medical device sound dampening. The recall arose from the discovery that this material could degrade in two ways:

Particle release. As the foam aged, particularly when exposed to high heat and humidity (conditions present in homes where the devices were used), particles of degraded foam could break off and be inhaled by the user or could enter the device's air path.

Chemical off-gassing. The foam released volatile organic compounds (VOCs) including diethylene glycol, dimethyl diazene, phenol, toluene diisocyanate, and other potentially toxic chemicals. The chemicals could be inhaled by users during normal device operation.

The exposure was particularly significant because:

CPAP users typically operate the devices for 6-8 hours every night. Cumulative exposure over years of nightly use produced substantial total exposure.

The exposure was directly to the respiratory system. The contaminated air was inhaled into the lungs without intervening barriers.

The user population included many people with already compromised respiratory function (sleep apnea, COPD), making them potentially more vulnerable to additional respiratory insults.

The cleaning practices recommended by Philips, including the use of ozone cleaning devices that the FDA later identified as potentially accelerating foam degradation, may have made the problem worse for users following manufacturer recommendations.

The June 2021 recall

Philips initiated the recall in June 2021, classifying it as a Class I recall — the FDA's most serious recall category indicating reasonable probability of serious adverse health consequences or death.

The recall covered approximately 3.5 million devices including:

DreamStation (the most commonly named device in litigation) DreamStation Go SystemOne Q-series SystemOne ASV4 series DreamStation ASV DreamStation ST, AVAPS OmniLab Advanced+ Various ventilator models including the V60, V60 Plus, A-Series BiPAP A40, A30

Approximately 80% of recalled devices were CPAP machines used for sleep apnea. The remaining 20% were ventilators and BiPAP devices used for various respiratory conditions.

The FDA reported receiving more than 105,000 complaints about Philips CPAP medical devices by June 2023, including 385 reports of PE-PUR foam-related deaths. These figures continued to grow as the recall progressed.

The remediation process was extended and incomplete. Philips initially indicated that replacement devices would be available within 12-18 months. The actual replacement and remediation process extended over 3+ years and was complicated by ongoing FDA enforcement actions.

Alleged injuries

The personal injury claims allege various injuries from PE-PUR foam exposure:

Lung cancer. The most-litigated cancer claim. PE-PUR degradation chemicals include known and suspected carcinogens.

Liver cancer. Several plaintiffs allege liver cancer from chemical exposure through CPAP use.

Kidney cancer. Kidney cancers allegedly caused by chronic exposure to PE-PUR degradation products.

Multiple myeloma and other blood cancers. Some plaintiffs allege blood cancers from chemical exposure.

Respiratory conditions. Chronic obstructive pulmonary disease, pulmonary fibrosis, asthma exacerbation, and other respiratory conditions allegedly caused or worsened by PE-PUR exposure.

Sinusitis and chronic infections. Persistent sinus problems and chronic airway infections.

Chemical poisoning syndrome. General toxic exposure symptoms from chronic chemical inhalation.

Cardiovascular conditions. Some plaintiffs allege cardiovascular effects from chronic chemical exposure.

The cancer claims have generally been considered the strongest and most valuable cases in the litigation. The settlement framework reflects this with tiered compensation based on diagnosis type and severity.

The September 2023 economic loss settlement

The first major settlement resolved economic loss claims. The framework:

Settlement amount. $445 million allocated to consumers who purchased, rented, or leased recalled CPAP, BiPAP, or ventilator devices.

Total fund. $479 million when including class-action attorneys' fees and administration costs.

Coverage. Approximately 3.5 million device owners potentially included in the class.

Compensation structure. Tiered based on whether the consumer received a replacement device, the type of device, and other factors. Individual recoveries typically in the $250-$1,500 range.

Court approval. Preliminary approval October 2023, final approval December 11, 2023.

Implementation. Claims process administered through the MDL 3014 settlement website.

The economic loss settlement resolved the consumer class action component of the litigation. It didn't address personal injury claims, which proceeded separately through the personal injury settlement track.

The April 2024 personal injury settlement

The $1.075 billion personal injury settlement resolved most personal injury claims:

Settlement amount. $1.075 billion for personal injury claims.

Medical monitoring fund. Additional $25 million for medical monitoring of users who hadn't yet developed compensable injuries.

Combined framework. Total $1.1 billion settlement framework.

Eligibility tiers. Compensation tiered based on cancer type, severity of injury, and exposure duration. Specific cancer types and severities receive different tier compensation amounts.

Estimated per-person amounts. Estimated $100,000 to $500,000 for cancer claims, with higher amounts for severe cases. Lower amounts for less severe respiratory conditions.

Coverage. Most personal injury claims in MDL 3014, plus parallel state court actions where Philips chose to include them.

Tolling agreement registry. Tens of thousands of additional claims were registered on tolling agreements (legal agreements pausing the statute of limitations while settlement negotiations occurred) and are being addressed through the settlement framework.

The settlement was driven by several factors:

Internal Philips documents revealed during discovery showed the company received foam-related complaints since 2008. The documents would have been damaging at trial.

Daubert proceedings on scientific causation were generally favorable to plaintiffs.

Bellwether trial preparations were advancing, with trial dates approaching in 2024-2025.

Philips faced not just civil liability but ongoing FDA enforcement and a consent decree restricting manufacturing operations. Resolving civil litigation was strategically important for the company's broader business position.

The settlement framework processes individual claims through a settlement administrator. Eligible claimants complete claim forms, submit supporting documentation (medical records, device use records, etc.), and receive determinations from the administrator. Disputes can be appealed through procedures specified in the settlement agreement.

State court tracks outside the settlement

Some personal injury cases remain outside the federal settlement framework:

Cases that didn't transfer to MDL 3014. Some plaintiffs filed in state court and successfully resisted Philips's attempts to remove cases to federal court. Various state procedural rules and jurisdictional doctrines have produced cases that remain in state systems.

January 2026 Kentucky remand. A notable example: Judge Conti sent back to Kentucky state court a CPAP cancer lawsuit involving a Kentucky woman alleging rare cancer from DreamStation use. Philips had argued the case belonged in MDL and that a local medical equipment supplier was added only to block federal jurisdiction. The court rejected Philips's argument, finding that Kentucky's pleading rules are intentionally lenient and that the claims against the supplier were sufficient.

Massachusetts cases. Some Massachusetts cases proceeded in state court alongside the federal MDL.

Various other state court actions. Additional cases in Pennsylvania, New York, Florida, and other states continue separately from the federal framework.

For cases outside the federal settlement, the procedural and substantive posture is more uncertain than for cases in the settlement framework. Some state court cases may eventually settle on terms similar to the federal framework; others may proceed to trial with different outcomes.

Who still qualifies to file

For potential new plaintiffs in 2026, the procedural posture is more limited than it was during active litigation:

Settlement deadline. The settlement framework had registration deadlines that have largely passed. New cases filing into the federal MDL face procedural restrictions on participation in the settlement.

Statute of limitations. Cancer cases must be filed within applicable state limitations periods. The discovery rule extends limitations in some cases (when the connection between cancer and CPAP use wasn't known until later), but the rule has limits. Cases involving cancers diagnosed before extensive public awareness of the connection (pre-2021) may face limitations issues.

State court availability. For some cases that don't fit into the federal settlement framework, state court filings remain available. The procedural analysis is state-specific.

Wrongful death cases. Estates of deceased plaintiffs can pursue wrongful death claims subject to applicable limitations periods.

Eligibility requirements for cases that may still be filed:

Documented use of recalled device. Records showing the consumer used a CPAP, BiPAP, or ventilator covered by the June 2021 recall.

Documented qualifying injury. Medical records establishing one of the conditions allegedly caused by PE-PUR exposure.

Temporal proximity. Connection between device use and injury that's plausible given the latency periods for the relevant conditions.

No significant alternative causation. Cases with strong alternative causes (heavy smoking with lung cancer, occupational chemical exposure, etc.) face more difficult causation analysis.

For most potential plaintiffs in 2026, the procedural reality is that the most productive path to recovery may have passed. The settlement framework provided the most accessible compensation; new cases face more uncertain procedural paths.

How CPAP compares to other mass torts

The Philips CPAP litigation has distinctive features compared to other recent mass torts:

Compared to Zantac MDL 2924 where the federal MDL was dismissed: Zantac plaintiffs faced catastrophic Daubert exclusion. CPAP plaintiffs avoided that fate, partly because internal Philips documents provided strong general causation evidence beyond expert testimony.

Compared to AFFF MDL 2873 where bellwether trials are still being scheduled: AFFF's settlement timeline is longer. CPAP resolution happened relatively quickly (3 years from recall to settlement) compared to AFFF's continuing trajectory.

Compared to 3M Combat Arms with the $6 billion global settlement: 3M required substantial bellwether litigation before settlement. CPAP settled before significant bellwether trials, suggesting Philips's exposure was clearer to the company than 3M's was to it.

Compared to Roundup litigation: Both involve product defect with substantial documented internal corporate knowledge of risk. Roundup has had multiple bellwether trials and continuing litigation; CPAP resolved through earlier settlement.

The broader procedural framework for mass tort settlements is covered in our overview of how mass tort litigation works. CPAP represents one of the faster-resolved major mass torts of the recent era.

Strategic considerations

For potential plaintiffs and current claimants:

Verify settlement registration status. For claims registered with the settlement administrator, verify the registration is current and complete. Missing deadlines or incomplete submissions can result in reduced compensation or claim denial.

For new potential claims. Engage experienced mass tort counsel immediately. The procedural windows are closing for many situations. Counsel can quickly evaluate whether the case fits into the settlement framework, state court alternatives, or has limitations period issues.

Document everything. Device receipts, prescription records, replacement device documentation, medical records, treatment history, contemporaneous photographs of device degradation if available. Documentation quality directly affects settlement compensation.

Be realistic about expected outcomes. The $100,000-$500,000 range cited in litigation reports reflects estimates that vary substantially case-by-case. Severe cases may exceed the range; less severe cases may fall below it. Don't make financial decisions based on speculative settlement projections.

Consider the broader regulatory context. FDA enforcement against Philips Respironics continues separately from civil litigation. The consent decree restricts ongoing manufacturing operations. Department of Justice investigations have produced additional consequences. The civil settlement doesn't end the regulatory exposure.

Watch for new product liability exposure. Philips has introduced replacement devices that have faced their own quality concerns. New product liability exposure for replacement devices may produce additional litigation tracks for users who experienced problems with replacement devices.

Coordinate with treating physicians. Medical records establishing the connection between device use and injury are critical. Treating physicians should be informed of the CPAP exposure history and the recall to ensure relevant documentation appears in the medical record.

For most consumers affected by the recall, the framework provides meaningful resolution. The economic loss settlement addressed device replacement costs for most users. The personal injury settlement provided compensation for users who developed cancer or other serious conditions. The remaining procedural questions involve cases outside the settlement framework, where individual analysis and experienced counsel are essential to evaluating the available options. The Philips CPAP litigation represents one of the more procedurally efficient major mass tort resolutions of recent years, with substantial compensation reaching affected users without the multi-year bellwether trial process that some comparable litigations have required.